---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-004547"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2022-03-24T23:59:59+00:00"
generated_at: "2026-06-26T18:30:22.007354+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Athira reports FY2021 net loss $54.9M; ACT-AD Phase 2 data on track for Q2 2022

## Summary
- Net loss $54.9M ($1.49/share) vs $19.9M in 2020; R&D spend $42.8M, up from $13.3M.
- Cash & investments $319.7M as of Dec 31, 2021; cash used in ops $43.1M in 2021.
- Topline ACT-AD Phase 2 Alzheimer's data expected Q2 2022; LIFT-AD Phase 3 enrollment to complete Q3 2022.
- First patient dosed in SHAPE Phase 2 in Parkinson's dementia / DLB; ATH-1020 Phase 1 initiated.
- Appointed Grant Pickering and Dr. Michael Panzara to Board; expanded management team.

## SEC filing metadata
- accession: 0000950170-22-004547
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2022-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000095017022004547/0000950170-22-004547-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000095017022004547/atha-20220324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-004547
- JSON: https://secwatch.observer/filing/0000950170-22-004547.json
- Plain text: https://secwatch.observer/filing/0000950170-22-004547.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.